Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation

Diabetes Research and Clinical Practice, pp. e38-e41, 2010.

Cited by: 21|Views4
EI WOS

Abstract:

We investigated the impact of metabolic syndrome (MS) on the occurrence of in-stent restenosis (ISR) and long-term major adverse cardiac events (MACEs), including cardiovascular death, myocardial infarction, and target vessel revascularization (TVR) during a follow-up period of 36 months after percutaneous coronary intervention (PCI) with...More

Code:

Data:

Your rating :
0

 

Tags
Comments